SG10201901076WA - Methods of treating alzheimer's disease - Google Patents
Methods of treating alzheimer's diseaseInfo
- Publication number
- SG10201901076WA SG10201901076WA SG10201901076WA SG10201901076WA SG10201901076WA SG 10201901076W A SG10201901076W A SG 10201901076WA SG 10201901076W A SG10201901076W A SG 10201901076WA SG 10201901076W A SG10201901076W A SG 10201901076WA SG 10201901076W A SG10201901076W A SG 10201901076WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- disease
- treating alzheimer
- patients
- mild
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
METHODSOF TREATING ALZHEIMER'S DISEASE Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and/or predictive biomarkers. (FIG. 16B) 126
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937472P | 2014-02-08 | 2014-02-08 | |
US201461971499P | 2014-03-27 | 2014-03-27 | |
US201462010265P | 2014-06-10 | 2014-06-10 | |
US201462082013P | 2014-11-19 | 2014-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201901076WA true SG10201901076WA (en) | 2019-03-28 |
Family
ID=52574436
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201901076WA SG10201901076WA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
SG11201606490YA SG11201606490YA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201606490YA SG11201606490YA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Country Status (16)
Country | Link |
---|---|
US (2) | US20170369559A9 (en) |
EP (2) | EP3900738A1 (en) |
JP (3) | JP6702878B2 (en) |
KR (1) | KR102476641B1 (en) |
CN (2) | CN106456729A (en) |
AU (2) | AU2015213741B2 (en) |
BR (1) | BR112016018205A8 (en) |
CA (1) | CA2938731A1 (en) |
ES (1) | ES2873248T3 (en) |
IL (1) | IL247085B (en) |
MX (2) | MX2016010237A (en) |
PL (1) | PL3102230T3 (en) |
RU (2) | RU2020111676A (en) |
SG (2) | SG10201901076WA (en) |
TW (3) | TW202239429A (en) |
WO (1) | WO2015120280A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3461834B1 (en) | 2013-03-13 | 2021-05-19 | Sage Therapeutics, Inc. | Neuroactive steroids |
US10779762B2 (en) * | 2015-10-20 | 2020-09-22 | Washington University | MRI method for in vivo detection of amyloid and pathology in the Alzheimer brain |
US11135313B2 (en) * | 2015-10-28 | 2021-10-05 | The Trustees Of The University Of Pennsylvania | Intrathecal administration of adeno-associated-viral vectors for gene therapy |
CN114113625A (en) * | 2016-01-20 | 2022-03-01 | 基因泰克公司 | High dose treatment for alzheimer's disease |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
TWI798751B (en) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
WO2018023036A1 (en) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment |
JP2019020206A (en) * | 2017-07-14 | 2019-02-07 | 株式会社島津製作所 | Cognitive disorder biomarker quantification method using mass analysis and mass spectroscope |
US11058729B2 (en) * | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
KR102555878B1 (en) * | 2020-04-23 | 2023-07-17 | 주식회사 바이오오케스트라 | Use of downregulated mirna for diagnosis and treatment |
WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
WO2022109267A2 (en) * | 2020-11-19 | 2022-05-27 | Regeneron Pharmaceuticals, Inc. | Genotyping by sequencing |
CA3223179A1 (en) * | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5589330A (en) | 1994-07-28 | 1996-12-31 | Genzyme Corporation | High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides |
US5849483A (en) | 1994-07-28 | 1998-12-15 | Ig Laboratories, Inc. | High throughput screening method for sequences or genetic alterations in nucleic acids |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US6239273B1 (en) | 1995-02-27 | 2001-05-29 | Affymetrix, Inc. | Printing molecular library arrays |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6152681A (en) | 1996-05-03 | 2000-11-28 | Arrowhead Systems, Llc | Container sweep for a palletizer and method |
ES2230631T3 (en) | 1997-03-20 | 2005-05-01 | F. Hoffmann-La Roche Ag | MODIFIED PRIMERS. |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6308170B1 (en) | 1997-07-25 | 2001-10-23 | Affymetrix Inc. | Gene expression and evaluation system |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
CA2299625A1 (en) | 1997-08-15 | 1999-02-25 | Affymetrix, Inc. | Polymorphism detection utilizing clustering analysis |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ES2375931T3 (en) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | HUMANIZATION OF ANTIBODY MURINO. |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2002510481A (en) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | Antibody variants and fragments thereof |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
JP2003512019A (en) | 1999-01-15 | 2003-04-02 | ジェネンテック・インコーポレーテッド | Polypeptide variants with altered effector functions |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6136541A (en) | 1999-02-22 | 2000-10-24 | Vialogy Corporation | Method and apparatus for analyzing hybridized biochip patterns using resonance interactions employing quantum expressor functions |
ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (en) | 1999-10-04 | 2002-10-23 | Medicago Inc | Method for regulating transcription of foreign genes in the presence of nitrogen. |
US6448010B1 (en) | 1999-10-06 | 2002-09-10 | Amersham Pharmacia Biotech, Inc. | Method for detecting mutations using arrayed primer extension |
US6709816B1 (en) | 1999-10-18 | 2004-03-23 | Affymetrix, Inc. | Identification of alleles |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
JP2003531588A (en) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | Multivalent antibodies and their uses |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN101940189A (en) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | Transgenic trasnchromosomal rodents for making human antibodies |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
BR0309145A (en) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Cells from which the genome is modified |
ATE503829T1 (en) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PL212899B1 (en) | 2002-12-16 | 2012-12-31 | Genentech Inc | Immunoglobulin variants and uses thereof |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
JPWO2005053742A1 (en) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | Medicament containing antibody composition |
JP5128935B2 (en) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | Humanized anti-TGF-β antibody |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
CL2007002070A1 (en) * | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | CHEMERIC OR HUMANIZED ANTIBODY, OR FRAGMENTS OF THEM, WHICH SPECIFICALLY ADHER TO AT LEAST AN EPITHOPE IN THE BETA-AMYLOID PROTEIN; NUCLEIC ACID MOLECULA THAT CODIFIES IT; COMPOSITION THAT UNDERSTANDS IT; YOUR USE TO TREAT NURSING |
PL2059533T3 (en) | 2006-08-30 | 2013-04-30 | Genentech Inc | Multispecific antibodies |
ES2640095T3 (en) | 2006-10-02 | 2017-10-31 | Ac Immune S.A. | Humanized antibody against beta-amyloid |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
JO3076B1 (en) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
CN105200097A (en) | 2008-10-20 | 2015-12-30 | 霍夫曼-拉罗奇有限公司 | Improved allele-specific amplification |
CN102229651A (en) * | 2011-06-08 | 2011-11-02 | 中南大学 | Amyloid protein intra-membrane segment for treating Alzheimer disease and application thereof |
GB201212334D0 (en) * | 2012-07-11 | 2012-08-22 | Warwick The | Therapeutic targets for alzheimers disease |
-
2015
- 2015-02-06 ES ES15706100T patent/ES2873248T3/en active Active
- 2015-02-06 EP EP21162693.2A patent/EP3900738A1/en active Pending
- 2015-02-06 CA CA2938731A patent/CA2938731A1/en active Pending
- 2015-02-06 CN CN201580018454.4A patent/CN106456729A/en active Pending
- 2015-02-06 EP EP15706100.3A patent/EP3102230B1/en active Active
- 2015-02-06 TW TW111100089A patent/TW202239429A/en unknown
- 2015-02-06 PL PL15706100T patent/PL3102230T3/en unknown
- 2015-02-06 WO PCT/US2015/014829 patent/WO2015120280A1/en active Application Filing
- 2015-02-06 RU RU2020111676A patent/RU2020111676A/en unknown
- 2015-02-06 TW TW104104200A patent/TWI769970B/en active
- 2015-02-06 CN CN202110043649.1A patent/CN112826930A/en active Pending
- 2015-02-06 AU AU2015213741A patent/AU2015213741B2/en active Active
- 2015-02-06 JP JP2016550546A patent/JP6702878B2/en active Active
- 2015-02-06 SG SG10201901076WA patent/SG10201901076WA/en unknown
- 2015-02-06 TW TW110102168A patent/TWI785472B/en active
- 2015-02-06 KR KR1020167024494A patent/KR102476641B1/en active IP Right Grant
- 2015-02-06 SG SG11201606490YA patent/SG11201606490YA/en unknown
- 2015-02-06 MX MX2016010237A patent/MX2016010237A/en unknown
- 2015-02-06 RU RU2016132162A patent/RU2720468C2/en active
- 2015-02-06 BR BR112016018205A patent/BR112016018205A8/en not_active Application Discontinuation
-
2016
- 2016-08-03 IL IL247085A patent/IL247085B/en active IP Right Grant
- 2016-08-05 MX MX2020010947A patent/MX2020010947A/en unknown
- 2016-08-17 US US15/239,225 patent/US20170369559A9/en not_active Abandoned
-
2019
- 2019-12-20 JP JP2019230686A patent/JP2020090497A/en not_active Withdrawn
-
2020
- 2020-09-16 AU AU2020233696A patent/AU2020233696A1/en not_active Abandoned
-
2021
- 2021-05-26 US US17/330,898 patent/US20220098288A1/en not_active Abandoned
- 2021-11-08 JP JP2021181553A patent/JP2022036946A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201901076WA (en) | Methods of treating alzheimer's disease | |
NZ739252A (en) | Monoclonal antibodies against bcma | |
WO2014190286A3 (en) | Methods and processes for non-invasive assessment of genetic variations | |
TW201613636A (en) | Methods of treating Alzheimer's Disease | |
MX2016001854A (en) | Compositions and method for treating complement-associated conditions. | |
NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
NZ700823A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
MA39776A (en) | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression | |
BR112016020053A2 (en) | methods of predicting the reaction of patients suffering from an inflammatory disorder, predicting the ability of patients to react, identifying patients suffering from an inflammatory disorder and its treatment, use of kits and kits | |
MX2016004283A (en) | Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare. | |
MX2016001439A (en) | Compositions and methods for identifying a risk of cancer in a subject. | |
WO2015168602A3 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease | |
EP3693742A3 (en) | Methods of detecting prostate cancer | |
EP3702470A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
TW201612518A (en) | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
MX2020006388A (en) | Biomarkers for diagnosis and prognosis of corneal ectatic disorders. | |
MX371426B (en) | Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment. | |
PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
WO2015181555A8 (en) | Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent | |
MX2018009274A (en) | Cancer. | |
WO2015004328A3 (en) | Method and a kit for assessment of vitamin e need | |
WO2014150819A3 (en) | Cancer biomarkers and methods of treating cancer | |
EP3674711A3 (en) | Biomarkers and methods for determining risk factors for alzheimer's disease |